Current evidence for active surveillance for intermediate risk prostate cancer: editorial on comparison of pathological and oncologic outcomes in "favorable risk" GS 3+4 and low risk GS6 prostate cancer by Gearman et al., Journal of Urology

Chirag G. Gordhan, Michael J. Whalen


Active surveillance is now endorsed as the preferred treatment approach for patients with National Comprehensive Cancer Network (NCCN) very-low and low risk prostate cancer.